Get the Stockscreener App
0.312
3.88%
-0.0126
Pre-market:
.30
-0.012
-3.85%
Lunai Bioworks Inc stock is traded at $0.312, with a volume of 7.30M.
It is down -3.88% in the last 24 hours and down -16.35% over the past month.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
See More
Previous Close:
$0.3246
Open:
$0.2598
24h Volume:
7.30M
Relative Volume:
0.37
Market Cap:
$11.32M
Revenue:
-
Net Income/Loss:
$-125.52M
P/E Ratio:
-0.0413
EPS:
-7.5468
Net Cash Flow:
$-5.72M
1W Performance:
-8.18%
1M Performance:
-16.35%
6M Performance:
-73.33%
1Y Performance:
+0.00%
1-Day Range:
$0.258
$0.333
1-Week Range:
$0.258
$0.4082
52-Week Range:
$0.1513
$1.66
Lunai Bioworks Inc Stock (LNAI) Company Profile
Name
Lunai Bioworks Inc
Sector
Industry
Phone
45 39179840
Address
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
Compare LNAI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LNAI
Lunai Bioworks Inc
|
0.312 | 11.32M | 0 | -125.52M | -5.72M | -7.5468 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lunai Bioworks Inc Stock (LNAI) Latest News
Oncotelic Therapeutics Announces Closing of a Strategic - GlobeNewswire
Lunai Bioworks Stock: $20 Million Patent Deal Puts Nasdaq Fight in Focus - TechStock²
A $20M Lunai deal adds two routes past the blood-brain barrier - Stock Titan
Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP - Yahoo Finance
Lunai Bioworks Completes $20 Million Preferred Equity Issuance - Intellectia AI
Lunai Bioworks initiates employee furloughs and salary deferrals to preserve liquidity - Investing.com
Lunai Bioworks Acquires Neurobridge IP Holdings in Major Patent-Backed Merger, Issues Series B Preferred Stock - Minichart
Lunai Bioworks Completes Merger and Issues Preferred Stock - TipRanks
Lunai Bioworks Acquires Neurobridge IP in Stock Deal, Issuing $20M Series B Preferred - TradingView
Lunai Bioworks (NASDAQ: LNAI) files proxy supplement; Reverse Split on ballot - Stock Titan
Lunai Bioworks (NASDAQ: LNAI) issues $20M preferred to acquire CNS patents, aid Nasdaq equity test - Stock Titan
LNAI Lunai Bioworks reports Q1 2026 EPS of negative 0.08, shares slip 0.81 percent with no analyst earnings estimates.Open Stock Signal Network - Newser
Lunai Bioworks Inc. announced that it has received $20 million in funding - marketscreener.com
Why is this micro-cap biotech stock up 150% today? - MSN
What's Behind The Jump In Lunai Bioworks Stock? - MSN
Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion - Quantisnow
SKAGI: Uppfærðar áherslur og skipulagsbreytingar - Weekly Voice
Lunai Bioworks, Inc. Announces Postponement of Special Meeting of Stockholders to May 8, 2026 - Weekly Voice
Lunai Bioworks Postpones Special Stockholder Meeting to May 8, 2026 to Ensure Quorum and Broker Voting Compliance 1 - Minichart
Lunai Bioworks Delays Special Stockholder Meeting to May - TipRanks
Lunai Bioworks (NASDAQ: LNAI) moves special vote to May 8 - Stock Titan
Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data - Quantisnow
2 biotech stocks bridging the gap between unmet need and next-gen medicine - MSN
Lunai Bioworks completes $20M transaction to acquire BBB - MSN
2 biotech stocks bridging the gap between unmet need and next-gen medicine | 2026-04-27 | Investing News - Stockhouse
Is Lunai Bioworks (LNAI) stock gaining bullish momentum |Beat Estimates - Newser
Stock Market Today: Nasdaq, S&P 500 Futures Gain While Dow Slips Amid Israel-Lebanon Ceasefire Extension—Intel, SAP, Lunai Bioworks In Focus (UPDATED) - MSN
LNAI Lunai Bioworks reports Q1 2026 EPS of negative 8 cents with no consensus estimates, notching a 1.77 percent share gain today.Earnings Miss - Newser
Stock Market Today: Nasdaq, S&P 500 Futures Gain While Dow Slips Amid Israel-Lebanon Ceasefire Extension—Intel, SAP, Lunai Bioworks In Focus (UPDATED) - Benzinga
Stock Market Today: Nasdaq, S&P 500 Futures Gain While Dow Slips Amid Israel-Lebanon Ceasefire Extension - Benzinga
LNAI Should I Buy - Intellectia AI
Lunai Bioworks to effect 10:1 reverse stock split - MSN
Is Lunai Bioworks (LNAI) stock a strong buy | Q1 2026: Earnings ReportExpert Momentum Signals - Xã Thanh Hà
Lunai Bioworks (LNAI) Stock Fill Price (Investor Concern) 2026-04-20Momentum Surge - Cổng thông tin điện tử tỉnh Lào Cai
Lunai Bioworks unit secures defense collaboration for AI chemical threat platform - MSN
Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships - Sahm
Lunai Bioworks signs letter of intent with Geneial for rare disease data collaboration - Investing.com Australia
Lunai Bioworks Inc Stock (LNAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):